Tumor Immunology and Immunotherapy

Edited by

Robert C. Rees
Director and Professor of Tumor Biology
The John van Geest Cancer Research Centre
Nottingham Trent University
Nottingham, UK
Contents

Abbreviations xvii
Contributor List xxi

1 Adaptive T-cell immunity and tumor antigen recognition 1
   Pedro Romero and Pierre G Coulie

2 Impact of ageing and body mass on cancer immunotherapy outcomes 15
   Gail D Sckisel, Arta M Monjazeb, Annie Mirsoian, Anthony E Zamora,
   Steven Grossenbacher, and William J Murphy

3 The potential of natural killer cells in cancer immunotherapy 31
   Thomas CC Tan, Jean-Marc Doisne, and Francesco Colucci

4 The tumor microenvironment: The role of tumor-associated macrophages
   in cancer progression and responses to therapy 43
   Russell Hughes and Munitta Muthana

5 ‘Hard’ and ‘soft’ loss of MHC class I expression in cancer cells 63
   Natalia Aptsiauri, Angel M. Garcia-Lora, and Federico Garrido

6 Modulation of the adaptive immune system through chronic inflammation
   and T-regulatory responses 79
   Angus G Dalgleish

7 Myeloid-derived suppressor cells: Immune-suppressive cells
   that facilitate tumor progression and promote and deter cancer-associated
   inflammation 95
   Pratima Sinha, Virginia Clements, Meghan Burke, Catherine Fenselau,
   and Suzanne Ostrand-Rosenberg

8 Triggering death receptors to promote cancer cell death 113
   Thomas J Sayers and Neil A Cross

9 Identification of tumor antigens for clinical evaluation 127
   Jayakumar Vadakekolathu, Amanda K Miles, David J Boocock,
   and Stephanie EB McArdle

10 Viral antigens as targets for prophylactic and therapeutic intervention
    in cancer 141
    Peter L Stern and Kenneth Oguejiofor

11 HER2/neu as a target for vaccine and antibody-directed therapies 155
    Constantin N Baxevanis and Sonia A Perez

12 Pre-clinical evaluation of immunotherapy: The case for prostate cancer
    and the TRAMP model 173
    Matteo Bellone, Sara Martina Parigi, and Elena Jachetti
13 Tumor-associated antigens characterized in a conceptual framework of biology, microenvironment, and therapy 189
*Per thor Straten, David Schrama, Jürgen C Becker, and Mads Hald Andersen*

14 Predictive biomarkers to better select patients for cancer immunotherapy 203
*Marius Strioga and Eric Tartour*

15 Viral platforms for expression of tumor antigens in cancer immunotherapy 217
*Karishma Rajani, Vanesa Alonso-Camino, Nicolas Boisgerault, and Richard Vile*

16 Translating research into clinical practice: lessons from the immunology and immunotherapy of haemopoietic malignancies 235
*Paul Moss*

17 DNA vaccines 251
*Lindy G Durrant, Wei Xue, Lee R Machado, Rachael L Metheringham, and Victoria A Brentville*

18 Programming the immune system through childhood infections: MUC1 tumor-associated antigen (TAA) as a disease-associated antigen (DAA) 265
*Uzoma K Iheagwara, Pamela L Beatty, Bianca Su-Wan Chan, Lora H Rigatti, Ted Ross, and Olivera J Finn*

19 Vaccination against myeloid leukaemias using newly defined antigens 281
*Susanne Hofmann, Ghazala Khan, Viktoriya Boncheva, Jochen Greiner, and Barbara-ann Guinn*

20 Immune-checkpoint blockade in cancer immunotherapy 295
*Patrick A Ott and F Stephen Hodi*

21 Multi-peptide cancer vaccines for clinical application 309
*Harpreet Singh-Jasuja, Toni Weinschenk, and Steffen Walter*

22 Adoptive T-cell therapy using TILs for the treatment of metastatic melanoma 327
*Marco Donia, Eva Ellebæk, and Inge Marie Svane*

23 Chimeric antigen receptor gene therapy in cancer 343
*John S Bridgeman and David E Gilham*

24 The vaccinal effect of monoclonal antibodies in cancer therapy 357
*Claire Deligne, Sophie Sibéril, and Jean-Luc Teillaud*

25 Antibody therapies: defining appropriate cell surface epitopes for targeting tumors 373
*Gabriele Multhoff and Michael Stangmaier*

26 Adoptive lymphocyte (stem cell) therapy in cancer 387
*Sophie Derniame and Aurore Saudemont*
27 Cancer stem cells (CSCs) and epithelial-to-mesenchymal transition (EMT): Tumor cell plasticity challenges immunotherapy 401
Tarik Regad and Morgan G Mathieu

28 Immune escape and ageing of the immune system compromises the immune response to tumor antigens 415
Ludmila Müller and Graham Pawelec

Index 433